Overview

Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

Status:
Completed

Trial end date:
2001-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the study drug is effective in the long-term treatment of primary or secondary pulmonary hypertension

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Iloprost